Novelion Therapeutics Inc. (NASDAQ:NVLN) Files An 8-K Other Events
Item 8.01. Other Events.
issued a press release announcing that the Toronto Stock Exchange
(the TSX) has granted the Companys request to voluntarily delist
its common shares, no par value per share, from the TSX effective
at the close of market on May 3, 2017. Following such delisting,
the Companys common shares will continue to trade on the Nasdaq
Global Select Market under the symbol NVLN. The press release is
attached as Exhibit 99.1 to this Current Report on Form 8-K and
is incorporated by reference into this Item 8.01.
|
Exhibit No.
|
Description
|
|
|
99.1
|
Press Release, dated April 19, 2017.
|
About Novelion Therapeutics Inc. (NASDAQ:NVLN)
Novelion Therapeutics Inc, formerly QLT Inc., is a Canada-based biopharmaceutical company. The Company is engaged in development of new standards of care for individuals living with rare diseases. The Company is focused on advancing its portfolio of rare disease therapies by investing in science and clinical development. The Company holds a portfolio of products through its subsidiary, Aegerion Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. The Company’s portfolio of products include MYALEPT and JUXTAPID. The Company is also developing zuretinol acetate for the treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes. Novelion Therapeutics Inc. (NASDAQ:NVLN) Recent Trading Information
Novelion Therapeutics Inc. (NASDAQ:NVLN) closed its last trading session down -0.10 at 10.35 with 68,669 shares trading hands.
